Diagnosis and treatment of rhinovirus respiratory infections

Antonio R Anzueto, Michael S. Niederman

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Acute upper viral respiratory infection (VRI) is the number one cause of illness for which patients seek medical care in the United States. Rhinoviruses, members of the family Picornaviridae, are the causative pathogens in more than half of VRIs, and they are associated with acute exacerbations of respiratory disease, including asthma, sinusitis, otitis media, and COPD. Owing to the lack of commercial availability of rapid and cost-effective laboratory tests to confirm the presence of VRI, the diagnosis is most commonly made empirically, based on patient history and physical examination. Currently, no antiviral agents that are active against picornaviruses are available for clinical use. Antimicrobial agents, frequently prescribed for VRIs, are not active against viruses, and their inappropriate and widespread use has contributed to an increase in antimicrobial resistance among bacteria commonly involved in respiratory tract infections. Several newer antiviral agents are being evaluated for treatment of VRIs. Although a variety of mechanisms and agents have been tested, few have shown significant clinical benefit in human trials. The most advanced antiviral agent in clinical trials is pleconaril, a novel viral capsid-binding inhibitor with potent and highly specific in vitro activity against the majority of serotypes of rhinoviruses and enteroviruses. Clinical trials of pleconaril for the treatment of VRIs have been conducted, and the role of pleconaril in patients with chronic lung disease is being evaluated.

Original languageEnglish (US)
Pages (from-to)1664-1672
Number of pages9
JournalChest
Volume123
Issue number5
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Rhinovirus
Respiratory Tract Infections
Picornaviridae
Antiviral Agents
Virus Diseases
Clinical Trials
Enterovirus
Capsid
Sinusitis
Otitis Media
Anti-Infective Agents
Chronic Obstructive Pulmonary Disease
Lung Diseases
Physical Examination
Disease Progression
Chronic Disease
Therapeutics
Asthma
Viruses
Bacteria

Keywords

  • Antiviral agents
  • Asthma
  • COPD
  • Otitis media
  • Pleconaril
  • Rhinoviruses
  • Sinusitis
  • Viral respiratory infection

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Diagnosis and treatment of rhinovirus respiratory infections. / Anzueto, Antonio R; Niederman, Michael S.

In: Chest, Vol. 123, No. 5, 01.05.2003, p. 1664-1672.

Research output: Contribution to journalArticle

Anzueto, Antonio R ; Niederman, Michael S. / Diagnosis and treatment of rhinovirus respiratory infections. In: Chest. 2003 ; Vol. 123, No. 5. pp. 1664-1672.
@article{f3071d8276184b71a14430f38d82da9b,
title = "Diagnosis and treatment of rhinovirus respiratory infections",
abstract = "Acute upper viral respiratory infection (VRI) is the number one cause of illness for which patients seek medical care in the United States. Rhinoviruses, members of the family Picornaviridae, are the causative pathogens in more than half of VRIs, and they are associated with acute exacerbations of respiratory disease, including asthma, sinusitis, otitis media, and COPD. Owing to the lack of commercial availability of rapid and cost-effective laboratory tests to confirm the presence of VRI, the diagnosis is most commonly made empirically, based on patient history and physical examination. Currently, no antiviral agents that are active against picornaviruses are available for clinical use. Antimicrobial agents, frequently prescribed for VRIs, are not active against viruses, and their inappropriate and widespread use has contributed to an increase in antimicrobial resistance among bacteria commonly involved in respiratory tract infections. Several newer antiviral agents are being evaluated for treatment of VRIs. Although a variety of mechanisms and agents have been tested, few have shown significant clinical benefit in human trials. The most advanced antiviral agent in clinical trials is pleconaril, a novel viral capsid-binding inhibitor with potent and highly specific in vitro activity against the majority of serotypes of rhinoviruses and enteroviruses. Clinical trials of pleconaril for the treatment of VRIs have been conducted, and the role of pleconaril in patients with chronic lung disease is being evaluated.",
keywords = "Antiviral agents, Asthma, COPD, Otitis media, Pleconaril, Rhinoviruses, Sinusitis, Viral respiratory infection",
author = "Anzueto, {Antonio R} and Niederman, {Michael S.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1378/chest.123.5.1664",
language = "English (US)",
volume = "123",
pages = "1664--1672",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Diagnosis and treatment of rhinovirus respiratory infections

AU - Anzueto, Antonio R

AU - Niederman, Michael S.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Acute upper viral respiratory infection (VRI) is the number one cause of illness for which patients seek medical care in the United States. Rhinoviruses, members of the family Picornaviridae, are the causative pathogens in more than half of VRIs, and they are associated with acute exacerbations of respiratory disease, including asthma, sinusitis, otitis media, and COPD. Owing to the lack of commercial availability of rapid and cost-effective laboratory tests to confirm the presence of VRI, the diagnosis is most commonly made empirically, based on patient history and physical examination. Currently, no antiviral agents that are active against picornaviruses are available for clinical use. Antimicrobial agents, frequently prescribed for VRIs, are not active against viruses, and their inappropriate and widespread use has contributed to an increase in antimicrobial resistance among bacteria commonly involved in respiratory tract infections. Several newer antiviral agents are being evaluated for treatment of VRIs. Although a variety of mechanisms and agents have been tested, few have shown significant clinical benefit in human trials. The most advanced antiviral agent in clinical trials is pleconaril, a novel viral capsid-binding inhibitor with potent and highly specific in vitro activity against the majority of serotypes of rhinoviruses and enteroviruses. Clinical trials of pleconaril for the treatment of VRIs have been conducted, and the role of pleconaril in patients with chronic lung disease is being evaluated.

AB - Acute upper viral respiratory infection (VRI) is the number one cause of illness for which patients seek medical care in the United States. Rhinoviruses, members of the family Picornaviridae, are the causative pathogens in more than half of VRIs, and they are associated with acute exacerbations of respiratory disease, including asthma, sinusitis, otitis media, and COPD. Owing to the lack of commercial availability of rapid and cost-effective laboratory tests to confirm the presence of VRI, the diagnosis is most commonly made empirically, based on patient history and physical examination. Currently, no antiviral agents that are active against picornaviruses are available for clinical use. Antimicrobial agents, frequently prescribed for VRIs, are not active against viruses, and their inappropriate and widespread use has contributed to an increase in antimicrobial resistance among bacteria commonly involved in respiratory tract infections. Several newer antiviral agents are being evaluated for treatment of VRIs. Although a variety of mechanisms and agents have been tested, few have shown significant clinical benefit in human trials. The most advanced antiviral agent in clinical trials is pleconaril, a novel viral capsid-binding inhibitor with potent and highly specific in vitro activity against the majority of serotypes of rhinoviruses and enteroviruses. Clinical trials of pleconaril for the treatment of VRIs have been conducted, and the role of pleconaril in patients with chronic lung disease is being evaluated.

KW - Antiviral agents

KW - Asthma

KW - COPD

KW - Otitis media

KW - Pleconaril

KW - Rhinoviruses

KW - Sinusitis

KW - Viral respiratory infection

UR - http://www.scopus.com/inward/record.url?scp=0038216548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038216548&partnerID=8YFLogxK

U2 - 10.1378/chest.123.5.1664

DO - 10.1378/chest.123.5.1664

M3 - Article

C2 - 12740288

AN - SCOPUS:0038216548

VL - 123

SP - 1664

EP - 1672

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -